CWP
OVID icon

Concord Wealth Partners’s Ovid Therapeutics OVID Stock Holding History

Concord Wealth Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-210
Closed -$1K – 1336
2022
Q1 		$1K Hold
210
– – ﹤0.01% 1231
2021
Q4 		$1K Buy
+210
New +$720 ﹤0.01% 1249

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Concord Wealth Partners's OVID Position: Q2 2022 in Review

Concord Wealth Partners sold out of Ovid Therapeutics (OVID) in Q2 2022, closing a stake of 210 shares — an estimated $1K sold.

Concord Wealth Partners first reported a position in OVID in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 55 funds tracked by Wall St. Rank hold OVID as of Q2 2022.

  • Concord Wealth Partners reported no remaining Ovid Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Concord Wealth Partners sold 210 Ovid Therapeutics shares in Q2 2022, an estimated $1K.
  • Concord Wealth Partners first reported a position in Ovid Therapeutics in Q4 2021 and held it in 2 quarters.
  • Concord Wealth Partners's Ovid Therapeutics position peaked at $1K in Q1 2022.
  • 55 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2022.

Based on Concord Wealth Partners's 13F filing for Q2 2022, filed 4 Aug 2022.